We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.43% | 1.15 | 1.02 | 1.255 | 1.27 | 1.27 | 1.27 | 733,994 | 16:35:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -2.92M | -0.0070 | -1.81 | 4.81M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/12/2024 10:28 | Nice £6K buy just before cop yesterday, let's hope it was someone in the know so to speak,well we are due news soon,we may be pleasantly surprised, maybe. | bri15 | |
29/11/2024 12:58 | chesty1 - sticky bun, currant bun, Chelsea bun or hot cross bun? | lord loads of lolly | |
29/11/2024 11:07 | Another stock for the bun | chesty1 | |
26/11/2024 11:53 | kingston - just goes to show - you can't trust what the scientists tell you! waterloo - as I keep pointing out to Nobby, it's McCarthy's job to keep the company running, which, despite serial failures by the scientists, he's succeeded in doing. I don't like what he does, but I think it's important to recognise where the problems lie, and it really isn't with McCarthy. Or are you of the opinion that they should have just been allowed to go under? | supernumerary | |
26/11/2024 11:29 | Some people really shouldn't be allowed to run companies., at least public ones. Macarthy being almost top of the list. (I can think of a few others). Serial failures. | waterloo01 | |
26/11/2024 10:59 | The company was in the money on the warrants of INC, and if exercised at that time and sold the shares in the market would have made a tidy profit. Instead, the company paid £75k to extend the time limit for those warrants exercisable at 19.5 p, but INC's shares have tanked today to 3.5 p. Those warrants are under the water, and the £75k paid is now completely sunk. What a disaster of the decision made by the CEO of IMM! Not only that he personally holds a lot of shares in INC so he has lost money there too, at least on paper. | kingston78 | |
26/11/2024 10:06 | lol - wearing your heart on your sleeve, Nobby! It looks more like another science disaster to me. Which will have to be rescued, yet again, by another successful McCarthy fund raising :¬) | supernumerary | |
26/11/2024 07:03 | Uh oh another McCarthy disaster! | nobbygnome | |
14/11/2024 17:38 | Another article on the cell therapy approach. Looks increasingly as though that's the way lupus treatment will ultimately go. BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic lupus erythematosus (SLE), providing further evidence that the emerging class of candidates can reset the immune system. Interest in using CAR-T cell therapies has taken off since German researchers posted data on five people with SLE in 2022. An update on the study in February showed eight SLE patients remained in remission. Patients had severe, progressive disease that was resistant to standard immunomodulating treatments. The researchers also reported data in systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM). BMS is part of a wave of drug developers, both large and small, that hustled CD19-directed CAR-T cell therapies into autoimmune trials in the aftermath of the initial SLE data drop. The Big Pharma is sharing data at ACR Convergence 2024, where it is presenting results that go beyond the existing abstract. [ ... ] | supernumerary | |
07/11/2024 12:55 | Nobby - I came across this by accident: hxxps://www.theatlan I can't get access to the original article, but from other reports it looks as though teclistamab might be a very valuable drug for lupus. Can you see the original paper? If it's cheap, effective, readily available, and approved (for at least something) then it might contribute to reluctance by Avion to run this trial. | supernumerary | |
29/10/2024 18:36 | qaz - looks like you need a new body then. | lord loads of lolly | |
17/10/2024 11:58 | but my BODDDDYYYYYYYYYYYYYY | qazwsxedc69 | |
17/10/2024 11:38 | My gut tells me no. ! | robward | |
17/10/2024 06:47 | Are Avion ever going to start the phase II/III…. | nobbygnome | |
17/10/2024 06:32 | STX, SBTX, BT, VOD, GDR, CPI? Need any more? It's taken longer than expected here, but it will come. Have a great day in your bedsit. | socionomics | |
06/10/2024 10:19 | Socionomics, most of the shares that you have recommended have turned out to be duds. | kingston78 | |
18/9/2024 12:27 | So so close now! | socionomics | |
17/9/2024 18:30 | 500 - Gap the stock! Could be tomorrow AM. Everything crossed for all genuine gamblers. | socionomics | |
16/9/2024 20:02 | It isn't even the year, let alone the week. | supernumerary | |
16/9/2024 19:32 | It feels like this is the week. We are so close now. | socionomics | |
21/8/2024 18:49 | + 100 : I need shares. | socionomics | |
15/8/2024 11:16 | It seems as Jane Austin wrote in Pride and Prejudice and paraphrasing: "It is a truth universally acknowledged that anyone who makes a future share price (direction) prediction may be both right and wrong, but that they will only ever highlight one of those conditions." Of course the algo driven trading knows where to put the price but for IMM this isn't at least for now much of a issue although it seems someone is keeping it in a range. PS agree with Nobby in 38701. | colsmith | |
14/8/2024 11:44 | Good banter guys. Let's keep this thread informative and humorous. Nobby versus Socio. Who will prove to be right and over what time frame. Will Nobby turn positive?Looking at the depth of the red next to the IMM part of my portfolio I'm rooting for Socio and wondering whether to double my holding at these levels in a reckless attempt to salvage something from this otherwise disastrous investment (to date". | husbod |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions